ISB Assistant Professor Dr. Sid Venkatesh is the co-first author of a paper in the journal Science. While at Washington University in St. Louis, Venkatesh and colleagues identified a novel gut microbial enzyme that impacts satiety-related signaling pathways in undernourished children treated with microbiota-directed complementary foods.
Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.
ISB researchers have developed a novel way to simulate personalized, microbiome-mediated responses to diet. They use a microbial community-scale metabolic modeling (MCMM) approach to predict individual-specific short-chain fatty acid production rates in response to different dietary, prebiotic, and probiotic inputs.
A new study unveils important insights and actionable protocols into providing equitable STEM experiences for high school students from historically marginalized communities. The research highlights the transformative power of informal STEM learning and the ease with which many organizations could provide these opportunities.
Infection, autoimmunity and cancer account for 40 percent of deaths worldwide. In a Cell Reports paper, ISB researchers detail how the human immune system works in common ways across diseases – findings that offer promising avenues for exploring multi-disease therapeutic strategies.
In a breakthrough discovery that changes how we understand T cells and with implications of how we can better engineer custom immune responses to fight disease, Institute for Systems Biology researchers showed that the different disease-fighting functions of different T cells are determined by the genetically encoded T-cell receptor sequence that are unique to those cells.
An ISB-led study showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease. The findings reinforce that there isn’t a one-size-fits-all approach, and provides important new avenues for further investigation.
ISB Associate Professor Dr. Sean Gibbons was named a Highly Cited Researcher for 2023. It is the second consecutive year Gibbons has earned the distinction. The Highly Cited Research list is generated annually by Clarivate, which says: “Of the world’s population of scientists and social scientists, Highly Cited Researchers are 1 in 1,000.”
By using a computer model to understand the adaptions of Mycobacterium tuberculosis (Mtb), the pathogen that causes tuberculosis, researchers at ISB have identified a network within Mtb that allows it to tolerate and resist drug therapies. This work is published in Cell Reports.
Supplementing the standard of treatment for Alzheimer’s disease patients with personalized lifestyle coaching leads to less cognitive decline compared to standard of treatment alone, according to an ISB-led two-year study. The results were published in the Journal of Alzheimer’s Disease.
Pregnant people who are vaccinated are less likely to contract COVID-19 than unvaccinated pregnant people, and those vaccinated and boosted are less likely to get COVID than those who are vaccinated only, according to the first-ever large study of boosters and pregnancy.
Dr. Jennifer Hadlock – an expert in machine learning, immune-mediated inflammatory disease, and maternal/fetal health – has been promoted to associate professor. The Hadlock Lab is an interdisciplinary team that aims to accelerate translational research by integrating clinical data into systems biology at scale.
Sara Calder recently joined ISB as Systems Health and STEM Coordinator, and is our second-ever AmeriCorps member. In this Q&A, Calder shares her education journey, her future plans, and much more.
Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.
The NCI awarded ISB a 5-year, $13 million grant to lead a comprehensive cancer center and study sequential combinations of targeted inhibitors and immunotherapies. The program is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.
New ISB research shows that different patient responses to statins can be explained by the variation in the human microbiome. The findings were published in the journal Med, and suggest that microbiome monitoring could be used to help optimize personalized statin treatments.
